News – Abpro Corporation

Press Releases

MAY 4, 2021

Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration

FEB 2, 2021

Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19

DEC 16, 2020

Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19

NOV 25, 2020

Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders

NOV 16, 2020

Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19

OCT 20, 2020

Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19

MAR 3, 2020

Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets

FEB 28, 2019

Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific Antibodies

NOV 29, 2016

Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody

OCT 13, 2016

GEN Roundup: Immunoassays: Life Science Critical Tools

MAY 20, 2016

Abpro Announces Agreements with Two Boston Hospitals

APR 25, 2016

Abpro Announces Investment and Partnership with Essex Bio

OCT 10, 2014

Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallenge

November 6, 2019

Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meeting

MAY 16, 2019

Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO Meeting